HGEN Humanigen, Inc. Stock Quote

HGEN [NASD]

Index	-	P/E	-	EPS (ttm)	-1.69	Insider Own	40.28%	Shs Outstand	43.49M	Perf Week	3.16%
Market Cap	980.81M	Forward P/E	4.60	EPS next Y	4.11	Insider Trans	-1.52%	Shs Float	30.83M	Perf Month	34.76%
Income	-59.30M	PEG	-	EPS next Q	-0.66	Inst Own	31.00%	Short Float	6.73%	Perf Quarter	40.77%
Sales	-	P/S	-	EPS this Y	27.30%	Inst Trans	1.75%	Short Ratio	2.48	Perf Half Y	-18.45%
Book/sh	1.78	P/B	10.63	EPS next Y	327.10%	ROA	-174.70%	Target Price	29.33	Perf Year	738.56%
Cash/sh	1.76	P/C	10.73	EPS next 5Y	12.50%	ROE	-302.90%	52W Range	1.55 - 33.95	Perf YTD	8.11%
Dividend	-	P/FCF	-	EPS past 5Y	60.20%	ROI	-	52W High	-44.71%	Beta	-1.39
Dividend %	-	Quick Ratio	6.20	Sales past 5Y	-	Gross Margin	-	52W Low	1110.58%	ATR	2.19
Employees	2	Current Ratio	6.20	Sales Q/Q	-	Oper. Margin	-	RSI (14)	58.70	Volatility	10.85% 13.64%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	-567.50%	Profit Margin	-	Rel Volume	0.43	Prev Close	18.92
Shortable	Yes	LT Debt/Eq	0.00	Earnings	-	Payout	-	Avg Volume	836.43K	Price	18.77
Recom	1.70	SMA20	2.65%	SMA50	42.41%	SMA200	39.99%	Volume	360,773	Change	-0.79%

Dec-23-20

Initiated

National Securities

Buy

$35

Dec-22-20

Initiated

Jefferies

Buy

$27

Oct-21-20

Initiated

Cantor Fitzgerald

Overweight

$25

Oct-14-20

Initiated

H.C. Wainwright

Buy

$31

Oct-01-20

Initiated

ROTH Capital

Buy

$25

Jan-10-21 08:00AM	Humanigen and EVERSANA Announce Partnership to Support the Launch and Commercialization of Lenzilumab for the Treatment of COVID-19 Business Wire
Jan-05-21 04:30PM	Humanigen to Present at Multiple Upcoming Investor Conferences Business Wire +5.57%
Dec-28-20 07:00AM	Humanigen Secures U.S. Patent for Lenzilumab in Preventing Cytokine Storm and Neurotoxicity Related to CAR-T Cell Therapy Business Wire -21.14%
Dec-20-20 03:40AM	What Type Of Shareholders Own The Most Number of Humanigen, Inc. (NASDAQ:HGEN) Shares? Simply Wall St.
Dec-17-20 08:00AM	Humanigen to Present at J.P. Morgan Healthcare Conference Business Wire +23.81%
07:00AM	Humanigen Announces Completion of Enrollment in Phase 1 Study of Ifabotuzumab in Glioblastoma Multiforme Business Wire
Dec-14-20 08:00AM	Humanigen to Present at Upcoming Investor Conferences Business Wire +26.29%
Dec-02-20 11:33PM	Is Humanigen, Inc. (HGEN) A Good Stock To Buy? Insider Monkey
Nov-23-20 04:05PM	Humanigen Australia Proprietary Limited Established to Facilitate Asia-Pacific Growth Plans Business Wire
Nov-11-20 07:00AM	Humanigen Reports Third Quarter and Nine Months Ended September 30, 2020 Financial Results Business Wire
Nov-06-20 09:59AM	Humanigen Spikes 13% On Positive Covid-19 Data For Lenzilumab SmarterAnalyst
08:52AM	Is a Surprise Coming for Humanigen (HGEN) This Earnings Season? Zacks
07:00AM	Humanigen Announces Positive Interim Phase 3 Data of Lenzilumab in Patients Hospitalized with COVID-19 Business Wire
07:00AM	Humanigen Announces Cooperative Research and Development Agreement with the Department of Defense to Develop Lenzilumab for COVID-19 Business Wire
Nov-04-20 04:05PM	Humanigen Announces ZUMA-19 Abstract Accepted for Presentation at American Society of Hematology 2020 Annual Meeting Business Wire
Nov-03-20 09:01AM	Humanigen Inks First Asia Licensing Deal For Its Covid-19 Treatment SmarterAnalyst
07:30AM	Humanigen Executes Licensing Agreement for Lenzilumab in COVID-19 with KPM Tech/Telcon RF Pharmaceutical for South Korea and the Philippines Business Wire
Nov-01-20 05:58AM	Humanigen Treats First Patient in Late-Stage COVID-19 Trial SmarterAnalyst
Oct-30-20 02:05PM	Humanigen Announces First Patient Dosed at MedStar Washington Hospital Center in Phase 3 Clinical Study of Lenzilumab in COVID-19 Business Wire
Oct-29-20 07:00AM	Humanigen Announces First Patient Dosed in NIH ACTIV-5/Big Effect Trial Evaluating Lenzilumab for COVID-19 Business Wire -9.13%
Oct-27-20 04:01PM	Humanigen to Present at Upcoming Investor Conferences Business Wire -9.63%
Oct-13-20 12:48PM	NIH to test AbbVie, Boehringer Ingelheim drug in combination with remdesivr MarketWatch
11:00AM	National Institutes of Health Launches its ACTIV-5 "Big Effect Trial" Evaluating Humanigens Lenzilumab as Potential COVID-19 Therapy Business Wire
Oct-05-20 10:20AM	Humanigen's stock soars in active trading after upbeat report on lenzilumab in severe COVID-19 MarketWatch +23.25%
Oct-02-20 08:00AM	Humanigen Announces COVID-19 Case Report Demonstrating Rapid Resolution and Discharge after Single IND Emergency Use Authorization of Lenzilumab Business Wire
08:00AM	Humanigen Announces COVID-19 Case Report Demonstrating Rapid Resolution and Discharge after Single IND Emergency Use Authorization of Lenzilumab(TM) ACCESSWIRE
07:00AM	Humanigen Announces Lenzilumab in COVID-19 Program Updates Business Wire
07:00AM	Humanigen Announces Lenzilumab in COVID-19 Program Updates ACCESSWIRE
Sep-23-20 07:30AM	Humanigen Announces Thermo Fisher Partnership to Expand Manufacturing for COVID-19 Therapeutic Candidate Lenzilumab ACCESSWIRE
07:00AM	Humanigen Announces Thermo Fisher Partnership to Expand Manufacturing for COVID-19 Therapeutic Candidate Lenzilumab Business Wire
Sep-22-20 04:50PM	Humanigen to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit ACCESSWIRE -6.41%
04:30PM	Humanigen to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit Business Wire
02:25PM	Humanigen Announces Closing of Public Offering of Common Stock ACCESSWIRE
02:00PM	Humanigen Announces Closing of Public Offering of Common Stock Business Wire
Sep-21-20 12:02PM	Will Humanigen (NASDAQ:HGEN) Spend Its Cash Wisely? Simply Wall St. +14.72%
Sep-17-20 09:10PM	Humanigen Announces Pricing of Public Offering of Common Stock and Commencement of Trading on Nasdaq Under the Symbol HGEN ACCESSWIRE +15.56%
08:30PM	Humanigen Announces Pricing of Public Offering of Common Stock and Commencement of Trading on Nasdaq Under the Symbol "HGEN" Business Wire
Sep-15-20 07:30AM	Humanigen Announces Proposed Public Offering of Common Stock and Subsequent Listing on NASDAQ ACCESSWIRE
01:00AM	Humanigen and Lonza Announce Collaboration to Expand Manufacturing of Humanigen's COVID-19 Therapeutic Candidate Lenzilumab ACCESSWIRE
Sep-14-20 07:00AM	Humanigen Announces Review of Lenzilumab Phase 3 Study in COVID-19 by Data Safety Monitoring Board Business Wire
Sep-04-20 05:00PM	Humanigen Announces One-for-Five Reverse Stock Split; Reverse Split Facilitates Potential Uplisting to Nasdaq ACCESSWIRE -8.91%
04:30PM	Humanigen Announces One-for-Five Reverse Stock Split Business Wire
Sep-02-20 06:21PM	LD Micro 360 Companies --Set to Present this Week. ACCESSWIRE -7.06%
08:00AM	Humanigen to Present at Upcoming Investor Conferences Business Wire
Sep-01-20 06:15PM	Humanigen to Host Investor KOL Conference Call ACCESSWIRE

Humanigen, Inc., a clinical stage biopharmaceutical company, develops proprietary monoclonal antibodies for immunotherapy and oncology treatments. The company's lead product candidate is Lenzilumab, a monoclonal antibody that targets and neutralizes granulocyte-macrophage colony-stimulating factor, which is in Phase Ib/II clinical trial in patients with chronic myelomonocytic leukemia, and for the treatment of juvenile myelomonocytic leukemia. It also develops Ifabotuzumab, a monoclonal antibody that targets EphA3 receptor, which has completed the Phase I dose escalation portion of a Phase I/II clinical trial in multiple hematologic malignancies; and HGEN005 an anti-EMR1 monoclonal antibody, which is in pre-clinical stage for the treatment of eosinophilic diseases. Humanigen, Inc. has a clinical collaboration agreement with Kite Pharma, Inc. to conduct a multi-center Phase Ib/II study of Lenzilumab in patients with relapsed or refractory diffuse large B-cell lymphoma; and a cooperative research and development agreement with the Department of Defense to assist in the development of lenzilumab in advance of a potential emergency use authorization for COVID-19. The company was formerly known as KaloBios Pharmaceuticals, Inc. and changed its name to Humanigen, Inc. in August 2017. Humanigen, Inc. was founded in 2000 and is based in Burlingame, California.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
NOMIS BAY LTD.	10% Owner	Jan 19	Sale	19.81	50,000	990,500	6,173,532	Jan 19 06:35 PM
NOMIS BAY LTD.	10% Owner	Jan 15	Sale	18.23	30,000	546,870	6,223,532	Jan 19 06:35 PM
NOMIS BAY LTD.	10% Owner	Jan 14	Sale	18.07	25,000	451,650	6,253,532	Jan 19 06:35 PM
NOMIS BAY LTD.	10% Owner	Jan 12	Sale	18.43	14,577	268,613	6,278,532	Jan 13 05:22 PM
NOMIS BAY LTD.	10% Owner	Jan 11	Sale	19.00	10,423	198,037	6,293,109	Jan 13 05:22 PM
NOMIS BAY LTD.	10% Owner	Dec 28	Sale	22.20	500	11,101	6,303,532	Dec 31 04:30 PM
NOMIS BAY LTD.	10% Owner	Dec 24	Sale	22.05	8,401	185,234	6,304,032	Dec 28 05:17 PM
NOMIS BAY LTD.	10% Owner	Dec 23	Sale	21.09	45,000	948,870	6,312,433	Dec 28 05:17 PM
NOMIS BAY LTD.	10% Owner	Dec 22	Sale	20.00	50,000	1,000,000	6,357,433	Dec 23 04:06 PM
NOMIS BAY LTD.	10% Owner	Dec 21	Sale	19.46	25,000	486,445	6,407,433	Dec 23 09:17 AM
NOMIS BAY LTD.	10% Owner	Dec 18	Sale	15.76	62,700	988,321	6,469,733	Dec 23 09:17 AM

open in yahoo | open in reuters | open in google

Upgrade your FINVIZ experience